Lexatumumab

Cat. No.: HY-P99299

CAS No.: 845816-02-6

Target: Apoptosis

Pathway: Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research[1].

IC_{50} & Target

TRAIL-R2[1]

In Vitro

The combination of Cisplatin (HY-17394) with Lexatumumab synergistically inhibits the cell growth and enhanced apoptotic death[1].

Lexatumumab (0-10 μg/ml, 72 h) induces various degrees of cell death in the different melanoma cell lines[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line:	Melanoma cell lines
Concentration:	0.01, 0.1, 1.0 and 10.0 μg/ml
Incubation Time:	72 h
Result:	Induced various degrees of cell death in the different cell lines.

In Vivo

Lexatumumab (10 mg/kg, i.v., twice a week) increases antitumor effect in vivo when combined with Dacarbazine (HY-B0078)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	FEMX-1 xenografts mice[2]
Dosage:	10 mg/kg, 10 mg/kg+Dacarbazine (62.5 mg/kg once a week, i.p. injection)
Administration:	i.v., twice a week
Result:	Increased antitumor effect in vivo when combined with Dacarbazine (HY-B0078). Induced cleavage of livin into its truncated, proapoptotic form, a compound previously shown to accelerate apoptosis.

REFERENCES

[1]. Belyanskaya LL, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer. 2007 Oct 22;6:66.

[2]. Engesæter B, et al. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One. 2012;7(9):e45492.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA